...
首页> 外文期刊>BJU international >Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
【24h】

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

机译:阿仑膦酸盐降低了雄激素剥夺治疗和严重骨质减少或骨质疏松症的前列腺癌患者的骨折风险。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To evaluate changes in bone mass and fracture risk in patients with prostate cancer on androgen-deprivation therapy (ADT) and with a basal T-score of >-2.0, who were treated with an oral bisphosphonate, as such patients treated with ADT are at increased risk of bone loss and bone fracture. PATIENTS AND METHODS: We selected 61 patients with prostate cancer treated with ADT; 31 were treated with oral alendronate 70 mg once-weekly and a control group of 30 were not. At baseline and 12 months we measured bone mineral density (BMD) of the lumbar spine, femoral neck and total hip by dual-energy X-ray absorptiometry. All patients had severe osteopenia or osteoporosis at baseline. The risk of femoral neck fracture was calculated at baseline and 12 months (Z-score 2.7). RESULTS: Patients treated with alendronate had a significant increase in BMD at the lumbar spine and femoral neck after 1 year of follow-up, with mean (sd) values of 1.06 (0.26) vs 1.01 (0.21) g/cm(2) at baseline (P < 0.001), and 0.75 (0.07) vs 0.73 (0.07) g/cm(2) (P = 0.03), respectively, while the control group had a significant loss of BMD at the total hip of 0.79 (0.14) vs 0.81 (0.13) g/cm(2) (P = 0.03). BMD was significantly improved at the three locations in patients treated with alendronate compared with the control group, with differences at the lumbar spine, femoral neck and total hip of 0.05 (0.07) vs 0.01 (0.10) (P = 0.001), 0.01 (0.04) vs -0.002 (0.03) (P = 0.04) and 0.01 (0.04) vs -0.01 (0.02) g/cm(2), respectively (P = 0.001). Patients treated with alendronate had a significant decrease in the fracture risk at the femoral neck, by -0.54 (1.29) (P = 0.04) after 1 year of follow-up. CONCLUSIONS: Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture.
机译:目的:评估接受口服双膦酸盐治疗的雄激素剥夺疗法(ADT)和基础T值> -2.0的前列腺癌患者的骨量和骨折风险的变化,例如接受ADT治疗的患者骨丢失和骨折的风险增加。患者与方法:我们选择了61例接受ADT治疗的前列腺癌患者。每周一次口服阿仑膦酸钠70 mg治疗31例,对照组30例不服用。在基线和12个月时,我们通过双能X射线吸收法测量了腰椎,股骨颈和全髋的骨矿物质密度(BMD)。所有患者在基线时均患有严重的骨质减少或骨质疏松。在基线和12个月时计算出股骨颈骨折的风险(Z得分2.7)。结果:阿仑膦酸盐治疗的患者在随访1年后腰椎和股骨颈的BMD显着增加,在(sd)平均值为1.06(0.26)vs 1.01(0.21)g / cm(2)基线(P <0.001)和0.75(0.07)vs 0.73(0.07)g / cm(2)(P = 0.03),而对照组的全髋关节BMD明显减少0.79(0.14) vs 0.81(0.13)g / cm(2)(P = 0.03)。与对照组相比,使用阿仑膦酸盐治疗的患者的三个部位的BMD均有明显改善,腰椎,股骨颈和全髋的差异为0.05(0.07)vs 0.01(0.10)(P = 0.001),0.01(0.04) )vs -0.002(0.03)(P = 0.04)和0.01(0.04)vs -0.01(0.02)g / cm(2)(P = 0.001)。用阿仑膦酸盐治疗的患者在随访1年后,股骨颈骨折的风险显着降低了-0.54(1.29)(P = 0.04)。结论:每周一次70 mg阿仑膦酸盐治疗可显着改善患有严重骨质减少或骨质疏松的前列腺癌患者和ADT患者的腰椎和股骨颈BMD,并显着降低股骨颈骨折的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号